Welcome to our dedicated page for Koru Med Sys news (Ticker: KRMD), a resource for investors and traders seeking the latest updates and insights on Koru Med Sys stock.
KORU Medical Systems, Inc. (NASDAQ: KRMD) is a medical technology company in the surgical and medical instrument manufacturing industry, focused on large-volume subcutaneous infusion solutions. News about KORU Medical frequently centers on its Freedom Syringe Infusion System, financial performance, regulatory milestones, and collaborations with biopharmaceutical partners.
Investors following KRMD news can expect regular updates on quarterly and annual financial results, including net revenue trends, core business performance, and contributions from Pharma Services and Clinical Trials. The company often provides revenue guidance and discusses metrics such as gross margin and cash position in its earnings-related press releases, which are also referenced in Form 8-K filings.
KORU Medical’s news flow also highlights regulatory and clinical developments. This includes FDA 510(k) submissions for the Freedom System to be used with specific biologic drugs, such as rare disease therapies and oncology biologics like PHESGO for HER2+ breast cancer. The company reports clinical and real-world evidence, including multicenter evaluations comparing the FreedomEdge Infusion System with manual push techniques in oncology and immunology settings, focusing on nurse satisfaction, patient comfort, and workflow efficiency.
Another key news category involves strategic collaborations and development agreements with pharmaceutical and medical technology partners. Examples include agreements to develop next-generation subcutaneous immunoglobulin infusion systems and to integrate the FreedomEdge pump into wearable infusion platforms for targeted antibiotic delivery in periprosthetic joint infection.
In addition, KORU Medical issues announcements about leadership appointments, equity awards, and participation in investor conferences, providing insight into its management priorities and engagement with the investment community. For ongoing coverage of KRMD, this news page aggregates company press releases and related updates so readers can monitor financial disclosures, regulatory progress, and partnership activity over time.
KORU Medical Systems (NASDAQ: KRMD) has signed a Phase III clinical supply agreement for a new enzyme replacement therapy targeting a rare endocrinological disease. This follows the successful validation of the KORU Medical Freedom System for subcutaneous infusion. The trial will evaluate bi-weekly infusions, with potential treatment impact for 10,000 patients globally. The experimental drug has been granted Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and Orphan Drug designations by the FDA and in Europe.
KORU Medical President and CEO, Linda Tharby, expressed pride in their device development for large volume subcutaneous delivery and emphasized the company's expanding role in administering rare disease drugs.
KORU Medical Systems, Inc. (NASDAQ: KRMD) reported Q1 2024 financial results with net revenues of $8.2 million, an 11% increase YoY. Gross profit increased by 23% to $5.1 million. The company reaffirmed its full year 2024 revenue guidance of $31.2-$32.2 million, reflecting growth of 10-13% YoY. KORU Medical continues to expand its Core business and Novel Therapies collaborations, aiming for increased value for customers, patients, and shareholders.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.